百济神州今年前三季度收入已超去年全年,两大核心肿瘤药单季度商业化表现亮眼。 11月12日晚间,百济神州(BGNE.NS;06160.HK;688235.SH)发布2024年三季报。前三季度营业收入191.36亿元,同比增长48.63%,其中前三季度产品收入189.86亿元,同比增长72.9%。 2023年,百济神州营业收入174.23亿元,其中产品收入155.04亿元。对比来看,无论是总收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."